Resmed Inc (NYSE: RMD) has reported E.P.S. of $2.12 for its first fiscal quarter (ending September 30) versus $1.49 for the same period a year ago — an increase of 42%. E.P.S. were $7.57 for the latest four quarters through September 30 versus $6.16 for the same period a year ago — an increase of 23%.
Recent Price Action
On 10/24/24, Resmed Inc (NYSE: RMD) stock rose modestly by 0.7%, closing at $239.05. Moreover, this advance was accompanied by unusually high trading volume at 194% of normal. Relative to the market the stock has been exceptionally strong over the last nine months and is unchanged during the last week.
Current PriceTarget Research Rating
With future capital returns forecasted to exceed the cost of capital, RMD is expected to continue to be a modest Value Builder.
Resmed has a current Value Trend Rating of C (Low Neutral). The Value Trend Rating reflects very contradictory signals from PTR’s two proprietary measures of a stock’s attractiveness. Resmed has a poor Appreciation Score of 15 but a good Power Rating of 76, producing the Low Neutral Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment